Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 326 followers
Latest posts
Last updated 10 days ago
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
10 days ago
Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Invitation to Roche’s Full Year Results 2024 Presentation
16 days ago
Roche will publish its Full Year Results of 2024 prior to the...
Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
about 1 month ago
PADOVA study showed numerical delay in motor progression and positive trends on...
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution
about 1 month ago
Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the...
Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
about 1 month ago
Vabysmo PFS is the first and only prefilled syringe containing a bispecific...
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
about 1 month ago
Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the...
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
about 1 month ago
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
about 1 month ago
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a...
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
about 1 month ago
Application is based on data from the phase III STARGLO study where...
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
about 2 months ago
Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially...
Roche reports update on Phase III SKYSCRAPER-01 study results
about 2 months ago
Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports...